The way forward in HCV treatment — finding the right path

  title={The way forward in HCV treatment — finding the right path},
  author={M. P. Manns and G. R. Foster and J. Rockstroh and S. Zeuzem and F. Zoulim and M. Houghton},
  journal={Nature Reviews Drug Discovery},
  • M. P. Manns, G. R. Foster, +3 authors M. Houghton
  • Published 2007
  • Medicine
  • Nature Reviews Drug Discovery
  • Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet available. Since the identification of HCV as the causative agent of non-A, non-B hepatitis, treatment has progressed rapidly, but morbidity and mortality rates are still predicted to rise. Novel, more efficacious and tolerable therapies are urgently needed, and a greater understanding of the viral life cycle has led to an… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    HCV NS5B polymerase inhibitors.
    • 37


    Publications referenced by this paper.
    An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
    • 810
    • PDF
    Challenges and successes in developing new therapies for hepatitis C
    • 393
    • PDF
    Hepatitis C therapeutics: current status and emerging strategies
    • 201
    Treating viral hepatitis C: efficacy, side effects, and complications
    • 615
    • PDF
    Projecting future complications of chronic hepatitis C in the United States
    • 581
    Prospects for a vaccine against the hepatitis C virus
    • 316